Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

British Journal of Cancer

Volumn 84, Issue 11, 2001, Pages 1443-1446

  Maxwell Armstrong, C A ^a   Durrant, L G ^b   Buckley, T J D ^a   Scholefield, J H ^a   Robins, R A ^a   Fielding, K ^a   Monson, J R T ^c   Guillou, P ^d   Calvert, H ^e   Carmichael, J ^b   Hardcastle, J D ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c CASTLE HILL HOSPITAL   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

105AD7; Anti idiotypic antibody; Colorectal cancer; Immunotherapy

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; DECAY ACCELERATING FACTOR; MONOCLONAL ANTIBODY 105AD7; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CARCINOMA; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLACEBOS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 17844367837     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1725     Document Type: Article

References (11)

1. Vaccine induced apoptosis - A novel clinical trial end point?
2. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36
3. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7 delays tumour growth by stimulating anti-tumor T cell responses
4. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody
5. Enhanced cell-mediated killing in patients immunized with a human monoclonal anti-idiotypic antibody 105AD7
6. 105AD7 cancer vaccine stimulates anti-tumour helper and cytotoxic T cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses
7. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, that mimics CD55
8. Cytotoxic T cell clone against rectal carcinoma induced by stimulation of a patients peripheral blood mononuclear cells with autologous cultured tumour cells
9. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105ADT
10. Antitumor immune response and Interleukin-2 production induced in colorectal cancer patienta by immunisation with human monoclonal anti-idiotypic antibody
11. Decay accelerating factor (CD55): A target for cancer vaccines